News stories about ADMA Biologics (NASDAQ:ADMA) have trended somewhat positive on Wednesday, according to Accern Sentiment. The research firm identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ADMA Biologics earned a coverage optimism score of 0.21 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 45.0318212818773 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Shares of ADMA Biologics (NASDAQ:ADMA) traded down $0.11 during midday trading on Wednesday, hitting $2.58. The stock had a trading volume of 154,400 shares, compared to its average volume of 66,349. The company has a current ratio of 2.36, a quick ratio of 1.35 and a debt-to-equity ratio of 2.26. ADMA Biologics has a 1-year low of $2.01 and a 1-year high of $5.79.
Several equities research analysts have recently weighed in on ADMA shares. Raymond James Financial raised ADMA Biologics from a “market perform” rating to an “outperform” rating and set a $5.00 target price on the stock in a research report on Tuesday, November 14th. ValuEngine lowered ADMA Biologics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Finally, Maxim Group reissued a “buy” rating and set a $8.00 target price (down previously from $13.00) on shares of ADMA Biologics in a research report on Monday, December 11th.
About ADMA Biologics
ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.